Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

@article{Aquilonius1983ClinicalPO,
  title={Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.},
  author={S. M. Aquilonius and S-{\AA}. Eckern{\"a}s and Per Hartvig and B O Lindstr{\"o}m and P. O. Osterman and Erik St{\aa}lberg},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={1983},
  volume={46 10},
  pages={929-35}
}
Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with… CONTINUE READING
6 Citations
16 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 16 references

The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration

  • SC Davison, NM Hyman, A Dehghan, K Chan
  • Meth Find Exptl Clin Pharmacol
  • 1981

The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis

  • K Chan, TN Calvey
  • J Neurol Neurosurg Psychiatry
  • 1981

Plasma concentration of pyridostigmine and effects in myasthenia gravis

  • E Stalberg, JV Trontelj, MS Schwartz
  • Clin Pharmacol Ther
  • 1978

Similar Papers

Loading similar papers…